Wednesday, 11 Dec 2019

You are here

TRIPLE Trial Results

Pegloticase has become an excellent option for management of patients with chronic refractory gout, although treatment may be limited by the development of anti-drug antibodies that lead to loss of serum urate (sUA) lowering effect. It is known that this loss of response is associated with reduced serum pegloticase levels (https://arthritis-research.biomedcentral.com/articles/10.1186/ar4497).

The investigators of the TRIPLE trial pose the question of whether an additional dose of 8 mg of pegloticase given in between the first and second doses would help to maintain serum pegloticase levels and therefore persistent urate lowering effect.

Dr. Kenneth Saag presented data from the TRIPLE study this morning. This is a multi-center, open label trial enrolling patients with chronic gout unable to maintain a serum uric acid level of 6 mg/dL or less. After discontinuing their background urate lowering agents, subjects received 3 weekly infusions of pegloticase 8 mg followed by biweekly doses to total 10 doses over 17 weeks. sUA was measured just before each dose and subsequent doses were given only if levels remained ≤6mg/dL. Serum pegloticase levels were also measured before each dose.

 

Results for the first 50 subjects were presented and included 22 responders, 21 non-responders and 7 subjects who dropped out. They found that subjects who responded had higher trough levels of pegloticase, and that levels 1-week post-infusion predicted responsiveness to the drug, with an overall response rate of 44% in subjects who received the additional dose. I think we will all be anxiously awaiting more results of this study!

Add new comment

More Like This

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β). 

Patients Prefer Nurse Led Care for their Gout

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.